0
World
Hongkongers to pay only HK$240 a year for leukaemia drug after system shake-up
May 6, 2026
Scroll
Posted 1 hour ago by
More than 400 cancer patients are set to benefit from Hong Kong health authorities’ decision to subsidise a leukaemia drug, and will go from paying up to HK500,000 (US63,800) a year for treatment to forking out just HK240. The Hospital Authority said on Wednesday that it began subsidising the medication, Dasatinib, in April, with the government expected to set aside an additional HK49 million in annual spending to help cover the cost.
As part of the move, Dasatinib was reclassified from a...
South China Morning Post
Coverage and analysis from Hong Kong. All insights are generated by our AI narrative analysis engine.
Hong Kong
Bias: lean left
People's Voices (0)
Leave a comment
0/500
Note: Comments are moderated. Please keep it civil. Max 3 comments per day.